Praxis Moves Away From Depression With Surprising Phase II/III Failure
With GABA-A modulator PRAX-114 missing all endpoints in a monotherapy study, Praxis will cease development of that drug and focus on its candidates for essential tremor and epilepsy.
You may also be interested in...
The companies reported positive Phase III data in postpartum depression, a market opportunity of up to half a million women in the US with a condition that remains underdiagnosed.
The drug may have enough efficacy for approval, but data fell short of the benchmark seen as necessary for commercial adoption
Public Company Edition: There was just one initial public offering during the past two weeks, but another biotech-focused SPAC went public and Gingko Bioworks announced a high-value SPAC merger. Also, Insmed and Dynavax offerings led recent public company financings.